GE shares jump again as Wall Street loves Danaher deal

UBS analyst Peter Lennox-King believes this new source of cash for GE, as well as the benefits, is a boon for the company.

“The sale of GE BioPharma to Danaher effectively puts the leverage question to bed,” Lennox-King said.

Deutsche Bank analyst Nicole DeBlase was the odd one out among the group, however, despite raising the firm’s price target on GE to $11 a share.

“GE is left with the less attractive parts of the Healthcare business,” DeBlase said of the deal.

Here’s what major Wall Street analysts said about GE’s deal.

Be the first to comment

Leave a Reply

Your email address will not be published.